L-serine

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: memory focus mood

Research Overview

Across the abstracts, L-serine emerges primarily as a central metabolic node rather than a single-disease therapy. The most studied areas include (i) neurometabolism and neurotransmission—particularly the L-serine → D-serine axis that modulates NMDA receptor co-agonism and links astrocytic glycolysis/lactate signaling to synaptic and cognitive function; (ii) systemic metabolic homeostasis, where serine connects glycolysis, transamination, glycine and folate-mediated one-carbon metabolism, and lipid (sphingolipid/phospholipid) synthesis; and (iii) translational “platform” uses of serine chemistry/transport, such as improving oral delivery of butyrate via a serine ester prodrug (SerBut), and incorporating L-serine into biomaterials or nanoparticles (e.g., kidney-targeted Klotho plasmid delivery; injectable chitosan hydrogels). Additional mechanistic work links serine accumulation to stress-adaptive metabolism in the heart (pressure overload–induced hypertrophy via YAP/GLUT1-driven Warburg-like remodeling).

The strongest evidence supported by these abstracts is that inadequate L-serine availability or dysregulated serine metabolism can be pathogenic—especially in the nervous system—through effects on membrane lipid composition (including deoxysphingolipid accumulation) and through downstream roles in neurotransmission and one-carbon metabolism. Correspondingly, supplementation shows the clearest therapeutic rationale in conditions of serine deficiency or impaired serine homeostasis (e.g., primary serine metabolism disorders and other states associated with low circulating serine), with additional supportive but more heterogeneous evidence in neuropathy-related contexts. Beyond supplementation, robust preclinical evidence also supports serine-enabled therapeutic strategies: SerBut improves disease severity and immune phenotypes in mouse models of autoimmune inflammation without broadly suppressing vaccine responses, and serine-containing delivery/material systems can enhance targeting, bioavailability, or mechanical performance in organ-specific interventions.

Key gaps include limited direct clinical efficacy data for L-serine supplementation outside clearly defined deficiency states, and an incomplete understanding of which patient subgroups (defined by circulating serine levels, flux, genetics, or “serine tolerance test” responses) are most likely to benefit. Mechanistically, more work is needed to reconcile tissue-specific sources and sinks of serine (brain-local synthesis vs. peripheral liver/kidney contributions), to define causal links between serine perturbations and organ outcomes (retina, heart, muscle aging), and to establish dosing, safety, and long-term metabolic consequences—particularly where serine intersects with tumor metabolism or immune regulation. For serine-based prodrugs, nanoparticles, and hydrogels, the main research needs are translational: comparative effectiveness versus existing therapies, pharmacokinetics/biodistribution in humans, manufacturing scalability, and rigorous safety assessment.

1. What conditions has L-serine been studied for?

  • Primary (genetic) disorders of serine metabolism / serine deficiency states: L-serine deficiency is linked to nervous system dysfunction, including via abnormal sphingolipid/phospholipid metabolism and increased deoxysphingolipids; L-serine has been used therapeutically in disorders associated with deficiency.

  • GRIN-related neurodevelopmental disorders (loss-of-function variants): A phase 2A, non-randomized, open-label, single-arm trial evaluated 52 weeks of L-serine in children with GRIN loss-of-function pathogenic variants (NCT04646447).

  • Neurological/psychiatric and CNS injury contexts (broader investigational use): Reviews cited investigation of L-serine and/or its metabolic products (D-serine, phosphatidylserine) across CNS injury and “a wide range” of neurological and psychiatric disorders.

  • Diabetic neuropathy: Reported therapeutic benefits in the review abstract.

  • Hyperhomocysteinemia: Reported therapeutic benefits in the review abstract (consistent with L-serine’s role in folate/methionine one-carbon metabolism).

  • Amyotrophic lateral sclerosis (ALS): Reported therapeutic benefits in the review abstract.

  • Autoimmune/inflammatory disease (indirectly, as a prodrug component): O-butyryl-L-serine (“SerBut,” a serine-esterified butyrate prodrug) improved disease in mouse models of rheumatoid arthritis (collagen-antibody-induced arthritis) and multiple sclerosis (EAE).

  • Cardiac pressure overload / compensatory hypertrophy (mechanistic association): In mice, acute pressure overload induced accumulation of glycolytic metabolites including l-serine in a YAP/GLUT1-dependent manner; this was linked to compensatory hypertrophy (not supplementation per se).

  • Kidney injury/fibrosis (as a nanoparticle component): L-serine was part of a nanoparticle system delivering a Klotho plasmid to injured tubular epithelial cells to prevent AKI-to-CKD transition in mice (gene therapy delivery platform rather than oral L-serine supplementation).

  • Intrauterine adhesions (as a biomaterial component): L-serine was used to induce fast gelation/mechanical reinforcement in an injectable hydrogel (with PRP) that improved outcomes in a rat IUA model (again, not dietary supplementation).

  • Gut inflammation and Enterobacteriaceae blooms (diet–microbe interaction): During intestinal inflammation, certain Enterobacteriaceae (e.g., E. coli LF82) gain a fitness advantage by catabolizing luminal L-serine; removing amino acids—particularly L-serine—from diet blunted inflammation-associated blooms in the model described.

  • Brain synaptic/cognitive function (mechanistic): In male mice, astrocyte CB1 receptor signaling shifts glycolysis toward lactate-dependent production of D-serine; memory deficits in astrocyte-CB1 knockout mice were rescued by D-serine and also by its precursor L-serine.

2. Does it work in treating those conditions? Summarize the evidence.

  • Serine deficiency / inborn errors of serine metabolism: The review concludes that there are disorders where humans cannot synthesize enough L-serine and that L-serine is effective in therapy of disorders associated with its deficiency. This is supportive but is a narrative synthesis in the abstract provided (details on trial design, effect sizes, and endpoints are not included here).

  • GRIN loss-of-function disorders: Evidence in the abstracts is preliminary. The abstract describes the first non-randomized, open-label, single-arm phase 2A trial with 52-week L-serine treatment and endpoints including safety and adaptive behavior/developmental scales. However, the abstract excerpt provided does not include results, so efficacy cannot be concluded from the text shown.

  • Diabetic neuropathy, hyperhomocysteinemia, ALS: The review reports “therapeutic benefits” in these conditions, but the abstracts provided do not include specific study designs, dosing, or quantitative outcomes. This supports plausibility and prior signals, but strength of evidence cannot be graded from these excerpts alone.

  • Autoimmune disease (SerBut, not plain L-serine): In mice, the serine-esterified butyrate prodrug (O-butyryl-L-serine) “substantially ameliorated disease severity” in rheumatoid arthritis and EAE models and modulated immune cell populations while not compromising vaccine responses. This supports efficacy for the prodrug strategy; it does not demonstrate that L-serine alone treats these diseases.

  • Cognition/synaptic function (mouse mechanistic rescue): In astrocyte CB1 receptor knockout male mice with impaired novel object recognition, the phenotype was rescued by D-serine and also by L-serine (and by lactate/HCAR1 agonist). This is proof-of-concept that L-serine availability can influence D-serine/NMDA receptor co-agonism and memory in a specific genetic/physiologic model; it is not clinical evidence for treating human cognitive disorders.

  • Cardiac hypertrophy, kidney fibrosis, intrauterine adhesions: The abstracts link L-serine to these areas mainly as a metabolite marker (heart) or as a material/drug-delivery component (kidney gene therapy nanoparticles; uterine hydrogel). They do not establish that oral L-serine supplementation treats these conditions.

  • Inflamed gut Enterobacteriaceae blooms: In the model described, dietary removal of amino acids—particularly L-serine—reduced luminal serine and blunted inflammation-associated blooms of E. coli LF82. This suggests that reducing dietary L-serine could be beneficial in certain inflammatory gut contexts by limiting pathobiont expansion (preclinical evidence; not a human trial).

3. What health benefits does it have?

  • Core metabolic and structural roles: L-serine is described as essential for protein synthesis, neurotransmission, folate and methionine cycles (one-carbon metabolism), and synthesis of sphingolipids and phospholipids. Its hydroxyl side chain contributes to protein polarity and is a major site for phosphorylation that regulates protein function.

  • Nervous system support when deficient: The abstracts link L-serine deficiency to nervous system impairment, particularly via abnormal lipid metabolism (including increased deoxysphingolipids). Supplementation is reported to be beneficial in disorders associated with deficiency.

  • Potential neuromodulatory/cognitive relevance via D-serine: In mice, astrocytic metabolism can route glycolysis toward L-serine and then D-serine production, influencing NMDA receptor co-agonist site occupancy and memory performance; L-serine rescued a memory deficit in a specific knockout model.

  • Systemic metabolic “node” with multi-tissue implications: A review abstract emphasizes L-serine as a central metabolic hub connecting carbohydrate metabolism, transamination, glycine/folate one-carbon metabolism, and downstream bioenergetic/biosynthetic pathways, with dysregulation implicated in nervous system, retina, heart, and aging muscle pathogenesis (preclinical/disease-association framing).

  • Therapeutic platform utility (not a supplement benefit per se): L-serine can be used in drug design/materials (e.g., butyrate prodrug SerBut to improve oral bioavailability; hydrogels; nanoparticles), enabling delivery or mechanical properties that improved outcomes in animal models.

4. Does it have any downsides or side effects?

The provided abstracts contain limited direct safety/side-effect reporting for L-serine supplementation.

  • Clinical safety data (limited in provided text): The GRIN trial explicitly includes tolerability/safety as primary endpoints, implying systematic safety assessment, but no adverse event results are included in the excerpt provided.

  • Potential context-dependent downside in gut inflammation: In inflamed gut conditions, luminal L-serine availability can provide a growth advantage to Enterobacteriaceae (e.g., E. coli LF82), and dietary removal of L-serine blunted blooms in the model described. This raises a plausible concern that high luminal serine availability could be undesirable in certain inflammatory dysbiosis contexts (preclinical; not proof of harm in humans).

  • Mechanistic caution: broad metabolic integration: Because L-serine sits at a central metabolic node (one-carbon metabolism, lipid synthesis), altering intake could theoretically have wide-ranging effects depending on baseline status and disease state; however, the abstracts do not provide specific adverse outcomes from supplementation.

  • Not all “serine-related” interventions equal: Some studies involve serine-containing prodrugs (SerBut) or biomaterials/nanoparticles; side effects of those platforms would not necessarily reflect L-serine supplement safety.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • GRIN loss-of-function variants (potentially beneficial; clinical trial underway): Children with GRIN loss-of-function pathogenic variants were treated with L-serine for 52 weeks in an open-label phase 2A trial (NCT04646447) assessing safety and adaptive/developmental outcomes. The abstract excerpt does not provide results, so benefit cannot be confirmed here, but this is a clear example of genotype-targeted use.

  • Genetic disorders of serine metabolism (beneficial when synthesis is insufficient): The review concludes that some disorders prevent adequate endogenous L-serine synthesis and that L-serine is effective in therapy of disorders associated with its deficiency—supporting a pharmacogenomic concept where genotype-driven deficiency predicts benefit (specific genes/variants are not named in the provided abstracts).

  • Astrocyte CB1 receptor knockout model (gene–nutrient interaction in mice): In male mice lacking astrocytic CB1 receptors, cognitive impairment was rescued by L-serine (and D-serine/lactate). This demonstrates a gene-dependent response in an animal model, but it is not directly translatable to human pharmacogenomic guidance.

  • Microbial genetics during inflammation (indirect “pharmacogenomics”): Enterobacteriaceae with intact L-serine utilization genes gained a competitive advantage in the inflamed gut; removing dietary L-serine reduced blooms. This is not human host genetics, but it suggests that microbial gene content can influence whether dietary serine is helpful or potentially counterproductive in inflammatory states.

References

  1. A walk through tau therapeutic strategies.
    Santosh Jadhav, Jesus Avila, Michael Schöll, Gabor G Kovacs, Enikö Kövari, Rostislav Skrabana, Lewis D Evans, Eva Kontsekova, Barbara Malawska, Rohan de Silva, Luc Buee, Norbert Zilka (2019) - Acta neuropathologica communications
  2. Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid.
    Milan Holeček (2022) - Nutrients
  3. YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overload.
    Toshihide Kashihara, Risa Mukai, Shin-Ichi Oka, Peiyong Zhai, Yasuki Nakada, Zhi Yang, Wataru Mizushima, Tsutomu Nakahara, Junco S Warren, Maha Abdellatif, Junichi Sadoshima (2022) - The Journal of clinical investigation
  4. A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice.
    Shijie Cao, Erica Budina, Michal M Raczy, Ani Solanki, Mindy Nguyen, Taryn N Beckman, Joseph W Reda, Kevin Hultgren, Phillip S Ang, Anna J Slezak, Lauren A Hesser, Aaron T Alpar, Kirsten C Refvik, Lucas S Shores, Ishita Pillai, Rachel P Wallace, Arjun Dhar, Elyse A Watkins, Jeffrey A Hubbell (2024) - Nature biomedical engineering
  5. A lactate-dependent shift of glycolysis mediates synaptic and cognitive processes in male mice.
    Ignacio Fernández-Moncada, Gianluca Lavanco, Unai B Fundazuri, Nasrin Bollmohr, Sarah Mountadem, Tommaso Dalla Tor, Pauline Hachaguer, Francisca Julio-Kalajzic, Doriane Gisquet, Roman Serrat, Luigi Bellocchio, Astrid Cannich, Bérénice Fortunato-Marsol, Yusuke Nasu, Robert E Campbell, Filippo Drago, Carla Cannizzaro, Guillaume Ferreira, Anne-Karine Bouzier-Sore, Luc Pellerin, Juan P Bolaños, Gilles Bonvento, L Felipe Barros, Stephane H R Oliet, Aude Panatier, Giovanni Marsicano (2024) - Nature communications
  6. Nanoparticle-mediated Klotho gene therapy prevents acute kidney injury to chronic kidney disease transition through regulating PPARα signaling in renal tubular epithelial cells.
    Hongyu Li, Yuying Ouyang, Haoran Lv, Hanzhi Liang, Siweier Luo, Yating Zhang, Haiping Mao, Tianfeng Chen, Wei Chen, Yiming Zhou, Qinghua Liu (2025) - Biomaterials
  7. Sources and Sinks of Serine in Nutrition, Health, and Disease.
    Michal K Handzlik, Christian M Metallo (2023) - Annual review of nutrition
  8. Injectable, degradable, and mechanically adaptive hydrogel induced by L-serine and allyl-functionalized chitosan with platelet-rich plasma for treating intrauterine adhesions.
    Hongyi Lv, Ruijuan Xu, Xiangyan Xie, Qianqian Liang, Wanting Yuan, Yuting Xia, Xue Ao, Shiqiao Tan, Lijuan Zhao, Jinrong Wu, Yi Wang (2024) - Acta biomaterialia
  9. Dietary L-serine confers a competitive fitness advantage to Enterobacteriaceae in the inflamed gut.
    Sho Kitamoto, Christopher J Alteri, Michael Rodrigues, Hiroko Nagao-Kitamoto, Kohei Sugihara, Stephanie D Himpsl, Malak Bazzi, Mao Miyoshi, Tatsuki Nishioka, Atsushi Hayashi, Tina L Morhardt, Peter Kuffa, Helmut Grasberger, Mohamad El-Zaatari, Shrinivas Bishu, Chiharu Ishii, Akiyoshi Hirayama, Kathryn A Eaton, Belgin Dogan, Kenneth W Simpson, Naohiro Inohara, Harry L T Mobley, John Y Kao, Shinji Fukuda, Nicolas Barnich, Nobuhiko Kamada (2020) - Nature microbiology
  10. l-Serine links metabolism with neurotransmission.
    Marianne Maugard, Pierre-Antoine Vigneron, Juan P Bolaños, Gilles Bonvento (2021) - Progress in neurobiology
  11. L-serine treatment in patients with GRIN-related encephalopathy: a phase 2A, non-randomized study.
    Natalia Juliá-Palacios, Mireia Olivella, Mariya Sigatullina Bondarenko, Salvador Ibáñez-Micó, Beatriz Muñoz-Cabello, Olga Alonso-Luengo, Víctor Soto-Insuga, Deyanira García-Navas, Laura Cuesta-Herraiz, Patricia Andreo-Lillo, Sergio Aguilera-Albesa, Antonio Hedrera-Fernández, Elena González Alguacil, Rocío Sánchez-Carpintero, Fernando Martín Del Valle, Erika Jiménez González, Lourdes Cean Cabrera, Ines Medina-Rivera, Marta Perez-Ordoñez, Roser Colomé, Laura Lopez, María Engracia Cazorla, Montserrat Fornaguera, Aida Ormazabal, Itziar Alonso-Colmenero, Katia Sofía Illescas, Sol Balsells-Mejía, Rosanna Mari-Vico, Maria Duffo Viñas, Gerarda Cappuccio, Gaetano Terrone, Roberta Romano, Filippo Manti, Mario Mastrangelo, Chiara Alfonsi, Bruna de Siqueira Barros, Mathilde Nizon, Cathrine Elisabeth Gjerulfsen, Valeria L Muro, Daniela Karall, Fiona Zeiner, Silvia Masnada, Irene Peterlongo, Alfonso Oyarzábal, Ana Santos-Gómez, Xavier Altafaj, Ángeles García-Cazorla (2024) - Brain : a journal of neurology
  12. A comprehensive review on signaling attributes of serine and serine metabolism in health and disease.
    Di Wu, Kejia Zhang, Faheem Ahmed Khan, Nuruliarizki Shinta Pandupuspitasari, Kaifeng Guan, Fei Sun, Chunjie Huang (2024) - International journal of biological macromolecules
  13. Injectable, stable, and biodegradable hydrogel with platelet-rich plasma induced by l-serine and sodium alginate for effective treatment of intrauterine adhesions.
    Xiangyan Xie, Xue Ao, Ruijuan Xu, Hongyi Lv, Shiqiao Tan, Jinrong Wu, Lijuan Zhao, Yi Wang (2024) - International journal of biological macromolecules
  14. L-serine synthesis via the phosphorylated pathway in humans.
    Giulia Murtas, Giorgia Letizia Marcone, Silvia Sacchi, Loredano Pollegioni (2020) - Cellular and molecular life sciences : CMLS
  15. L-Serine: a Naturally-Occurring Amino Acid with Therapeutic Potential.
    J S Metcalf, R A Dunlop, J T Powell, S A Banack, P A Cox (2018) - Neurotoxicity research
  16. L-Serine, an Endogenous Amino Acid, Is a Potential Neuroprotective Agent for Neurological Disease and Injury.
    Lisha Ye, Yechao Sun, Zhenglin Jiang, Guohua Wang (2021) - Frontiers in molecular neuroscience
  17. L-serine: a neglected amino acid with a potential therapeutic role in diabetes.
    Laurits J Holm, Karsten Buschard (2019) - APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  18. The role of astrocytes in depression, its prevention, and treatment by targeting astroglial gliotransmitter release.
    Yorley Duarte, Daisy Quintana-Donoso, Rodrigo Moraga-Amaro, Ivanka Dinamarca, Yordan Lemunao, Kevin Cárdenas, Tamara Bahamonde, Tabita Barrientos, Pedro Olivares, Camila Navas, Francisco J Carvajal, Yessenia Santibánez, Raimundo Castro-Lazo, María Paz Meza, Ramon Jorquera, Gonzalo I Gómez, Marina Henke, Rodrigo Alarcón, Laureen A Gabriel, Susanne Schiffmann, Waldo Cerpa, Mauricio A Retamal, Felipe Simon, Sergio Linsambarth, Fernando Gonzalez-Nilo, Jimmy Stehberg (2024) - Proceedings of the National Academy of Sciences of the United States of America
  19. Circulating and Urinary Concentrations of Malondialdehyde in Aging Humans in Health and Disease: Review and Discussion.
    Dimitrios Tsikas, Stefanos A Tsikas, Marie Mikuteit, Stefan Ückert (2023) - Biomedicines
  20. A novel marine-derived anti-acute kidney injury agent targeting peroxiredoxin 1 and its nanodelivery strategy based on ADME optimization.
    Ping Yu, Tanwei Gu, Yueyang Rao, Weimin Liang, Xi Zhang, Huanguo Jiang, Jindi Lu, Jianglian She, Jianmin Guo, Wei Yang, Yonghong Liu, Yingfeng Tu, Lan Tang, Xuefeng Zhou (2024) - Acta pharmaceutica Sinica. B


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!